Cargando…

Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein

Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an infectious disease that has become a serious burden on global public health. This study screened and yielded specific nanobodies (Nbs) against SARS-CoV-2 spike protein receptor bindi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Su, Qianling, Shi, Wei, Huang, Xianing, Wan, Yakun, Li, Guanghui, Xing, Bengang, Xu, Zhi Ping, Liu, Hongbo, Hammock, Bruce D., Yang, Xiaomei, Yin, Shihua, Lu, Xiaoling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9656363/ https://www.ncbi.nlm.nih.gov/pubmed/36359751 http://dx.doi.org/10.3390/cells11213355

Ejemplares similares

Nanobody-based label-free photoelectrochemical immunoassay for highly sensitive detection of SARS-CoV-2 spike protein
por: Chen, Yun, et al.
Publicado: (2022)

A dendritic/tumor fusion cell vaccine enhances efficacy of nanobody-based CAR-T cells against solid tumor
por: Sun, Shuyang, et al.
Publicado: (2023)

A potent neutralizing nanobody against SARS‐CoV‐2 with inhaled delivery potential
por: Gai, Junwei, et al.
Publicado: (2021)

Evaluation of SARS-CoV-2-Neutralizing Nanobody Using Virus Receptor Binding Domain-Administered Model Mice
por: Liu, Song, et al.
Publicado: (2022)

Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library
por: Yan, Junrong, et al.
Publicado: (2015)

Structural Biology of Nanobodies against the Spike Protein of SARS-CoV-2
por: Tang, Qilong, et al.
Publicado: (2021)

An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike
por: Schoof, Michael, et al.
Publicado: (2020)

Screening and antitumor effect of an anti-CTLA-4 nanobody
por: Wan, Ruirong, et al.
Publicado: (2018)

Nanobody-based chimeric antigen receptor T cells designed by CRISPR/Cas9 technology for solid tumor immunotherapy
por: Mo, Fengzhen, et al.
Publicado: (2021)

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression
por: Ding, Ziqiang, et al.
Publicado: (2023)

Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering
por: Verkhivker, Gennady
Publicado: (2022)

Highly sensitive detection of CTLA-4-positive T-cell subgroups based on nanobody and fluorescent carbon quantum dots
por: Wang, Wu, et al.
Publicado: (2019)

An ultra-potent synthetic nanobody neutralizes SARS-CoV-2 by locking Spike into an inactive conformation
por: Schoof, Michael, et al.
Publicado: (2020)

The use of nanobodies in a sensitive ELISA test for SARS-CoV-2 Spike 1 protein
por: Girt, Georgina C., et al.
Publicado: (2021)

Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein
por: Lu, Qizhong, et al.
Publicado: (2021)

Construction of a synthetic phage-displayed Nanobody library with CDR3 regions randomized by trinucleotide cassettes for diagnostic applications
por: Yan, Junrong, et al.
Publicado: (2014)

Nanobody: A Small Antibody with Big Implications for Tumor Therapeutic Strategy
por: Sun, Shuyang, et al.
Publicado: (2021)

A bispecific monomeric nanobody induces spike trimer dimers and neutralizes SARS-CoV-2 in vivo
por: Hanke, Leo, et al.
Publicado: (2022)

A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike
por: Fu, Ying, et al.
Publicado: (2022)

Correlation between the binding affinity and the conformational entropy of nanobody SARS-CoV-2 spike protein complexes
por: Mikolajek, Halina, et al.
Publicado: (2022)

Preventing SARS-CoV-2 Infection Using Anti-spike Nanobody-IFN-β Conjugated Exosomes
por: Lyu, Xiabing, et al.
Publicado: (2022)

2636. Discovery of Spike Identification (SpiID) Nanobody Panel for SARS-CoV-2 Vaccine Development
por: Li, Qi, et al.
Publicado: (2023)

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
por: Huo, Jiangdong, et al.
Publicado: (2020)

Author Correction: Neutralizing nanobodies bind SARS-CoV-2 spike RBD and block interaction with ACE2
por: Huo, Jiandong, et al.
Publicado: (2021)

Potent Neutralization of SARS-CoV-2 by Hetero-Bivalent Alpaca Nanobodies Targeting the Spike Receptor-Binding Domain
por: Ma, Huan, et al.
Publicado: (2021)

Therapeutische Nanobodies gegen SARS-CoV-2
por: Güttler, Thomas, et al.
Publicado: (2022)

SARS-CoV-2 nanobodies 2.0
por: Labroussaa, Fabien, et al.
Publicado: (2021)

CAMEL NANOBODIES NEUTRALIZE SARS-COV-2 VARIANTS
por: Hong, Jessica, et al.
Publicado: (2023)

A panel of nanobodies recognizing conserved hidden clefts of all SARS-CoV-2 spike variants including Omicron
por: Maeda, Ryota, et al.
Publicado: (2022)

A Novel Fusion Protein System for the Production of Nanobodies and the SARS-CoV-2 Spike RBD in a Bacterial System
por: Nagy-Fazekas, Dóra, et al.
Publicado: (2023)

The Development of a Novel Nanobody Therapeutic for SARS-CoV-2
por: Ye, Gang, et al.
Publicado: (2020)

A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies
por: Chen, Xun, et al.
Publicado: (2021)

Preclinical development of a novel CD47 nanobody with less toxicity and enhanced anti-cancer therapeutic potential
por: Ma, Linlin, et al.
Publicado: (2020)

Nanobody Repertoires for Exposing Vulnerabilities of SARS-CoV-2
por: Mast, Fred D., et al.
Publicado: (2021)

Prospects of Neutralizing Nanobodies Against SARS-CoV-2
por: Chen, Fangfang, et al.
Publicado: (2021)

Generation and Characterization of a Nanobody Against SARS-CoV
por: Li, Jiang-Fan, et al.
Publicado: (2021)

Nanobody-Functionalized Cellulose for Capturing SARS-CoV-2
por: Sun, Xin, et al.
Publicado: (2022)

High affinity nanobodies block SARS-CoV-2 spike receptor binding domain interaction with human angiotensin converting enzyme
por: Esparza, Thomas J., et al.
Publicado: (2020)

Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant
por: Verkhivker, Gennady
Publicado: (2022)

Nanobody repertoire generated against the spike protein of ancestral SARS-CoV-2 remains efficacious against the rapidly evolving virus
por: Ketaren, Natalia E., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_5qtinetlk5m7oac12ncuecasnn